Lauren Fong joined the Genea Biocells team on February 20, 2017 as a Senior Scientist. Dr. Fong earned a bachelor of arts in Molecular and Cell Biology from the University of California, Berkeley. After graduating, she joined Sangamo Biosciences where she worked to translate novel zinc finger nuclease/protease genome editing technology into therapies for Parkinson’s disease. In 2016, Dr. Fong earned a Ph.D. in Biomedical Sciences in the laboratory of Dr. Larry Goldstein at the University of California, San Diego. Her thesis work utilized stem cells and CRISPR/Cas9 genome-editing to elucidate the role of Alzheimer’s disease protein, APP, in brain lipoprotein metabolism and amyloid clearance in human astrocytes. At Genea Biocells, Dr. Fong is continuing her work in disease modeling by using human pluripotent stem cell derived muscle cells to develop therapeutics for neuromuscular diseases.